Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -59.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.43 | N/A | -59.85% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance. They emphasized the importance of addressing operational hurdles.
Management highlighted ongoing challenges in achieving profitability.
They acknowledged the need for strategic adjustments moving forward.
BioMarin's earnings report indicates significant challenges, particularly with their EPS falling short of expectations. The stock dropped 3.44% in response, reflecting investor concerns about the company's financial health and future profitability. Without any guidance provided, uncertainty remains about their strategic direction and recovery plans.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ASBURY AUTOMOTIVE GR
Feb 19, 2013